Lantern Pharma Price to Free Cash Flow Ratio 2020-2024 | LTRN

Lantern Pharma price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as

Lantern Pharma Price to Free Cash Flow Ratio 2020-2024 | LTRN

Lantern Pharma price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.8B
Vertex Pharmaceuticals (VRTX)$133.1B
Gilead Sciences (GILD)$120.2B
Bristol Myers Squibb (BMY)$109.8B
Regeneron Pharmaceuticals (REGN)$91B
CSL (CSLLY)$90.5B
GSK (GSK)$75.2B
Alnylam Pharmaceuticals (ALNY)$35.8B
Argenex SE (ARGX)$35.6B
BioNTech SE (BNTX)$26.3B
Biogen (BIIB)$25.2B
Illumina (ILMN)$24B
BeiGene (BGNE)$20B
Moderna (MRNA)$18B
Incyte (INCY)$16.1B
Genmab (GMAB)$15.3B
Vaxcyte (PCVX)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$12.8B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.6B
Exelixis (EXEL)$10.4B
Revolution Medicines (RVMD)$10.2B
QIAGEN (QGEN)$10B
Intra-Cellular Therapies (ITCI)$9.7B
Exact Sciences (EXAS)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.8B
Repligen (RGEN)$7.9B
Halozyme Therapeutics (HALO)$7.8B